PMID- 27342496
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20181202
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 24
IP  - 3
DP  - 2016 Jun
TI  - [Clinical Characteristics of 30 Hodgkin's Lymphoma Patients with Extranodal 
      Involvement].
PG  - 712-6
LID - 10.7534/j.issn.1009-2137.2016.03.014 [doi]
AB  - OBJECTIVE: To investigate the clinical characteristics, treatment outcomes, 
      prognosis, delayed toxicity of Hodgkin's lymphoma with extranodal Involvement. 
      METHODS: Thirty patients newly diagnosed as Hodgkin's lymphoma with extranodal 
      involvement from April 2008 to September 2014 were retrospectively analyzed. 
      RESULTS: Twenty-seven patients suffered from the advanced-stage diseases, their 
      major pathological changes were nodular sclerosis and mixed cellular type, the 
      most commonly involeved extranodal sites were the lung and bones, followed by the 
      liver, stomach and intestine. The common clinical presentation was assotiated 
      with the involved organs. Multivariate analysis showed that albumin and the 
      international prognostic score (IPS) were independent prognostic factors for 
      5-year DFS rate, the 5-year OS rate was only associated with IPS. Out of 20 
      patients received chemotherapy, 10 received the combined modality therapy. At the 
      median follow-up of 51 months, the estimated 5-year OS and PFS rates were 89.3% 
      and 78.9%, respectively. Delayed toxicities were observed in 3 patients, 
      including Ewing's sarcoma of llium, hyperplasia of mammary glands and diabetes 
      millitus. 5 patients kept fertility, no interstitial lung disease, lung cancer 
      and cardiovascular disease occurred. It was not found that patients died from the 
      treatment-related complications. CONCLUSION: The therapeutic strategies for the 
      Hodgkin's lymphoma patients with extranodal involvement should be similar to 
      normal Hodgkin's lymphoma.
FAU - Li, Yan-Fen
AU  - Li YF
AD  - Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
FAU - Zhao, Yu
AU  - Zhao Y
AD  - Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China. 
      E-mail: zhaoyu301@126.com.
FAU - Bo, Jian
AU  - Bo J
AD  - Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
FAU - Zhou, Ying
AU  - Zhou Y
AD  - Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
FAU - Ma, Chao
AU  - Ma C
AD  - Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
FAU - Wang, Quan-Shun
AU  - Wang QS
AD  - Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
FAU - Yu, Li
AU  - Yu L
AD  - Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
FAU - Liu, Dai-Hong
AU  - Liu DH
AD  - Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Combined Modality Therapy
MH  - Hodgkin Disease/*diagnosis/drug therapy/*pathology
MH  - Humans
MH  - Multivariate Analysis
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2016/06/28 06:00
MHDA- 2016/09/16 06:00
CRDT- 2016/06/26 06:00
PHST- 2016/06/26 06:00 [entrez]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
AID - 1009-2137(2016)03-0712-05 [pii]
AID - 10.7534/j.issn.1009-2137.2016.03.014 [doi]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Jun;24(3):712-6. doi: 
      10.7534/j.issn.1009-2137.2016.03.014.